NCT00782379 · OUTCOME

Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer · Source last updated 2013-11-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: Day 100

What was measured

Number of patients who experienced post-transplant complication (GVHD) as seen by clinical evidence

Analysis population: 17 patients were alive at Day 100 and eligible to be evaluated for grade 3-4 graft versus host disease

Groups in this outcome

Haploidentical Transplant

Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Haploidentical Transplant	17

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Haploidentical Transplant	2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
2

denoms

counts
group Id
OG000
value
17
units
Participants

description

Number of patients who experienced post-transplant complication (GVHD) as seen by clinical evidence

groups

description
Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant
id
OG000
title
Haploidentical Transplant

param Type

NUMBER

population Description

17 patients were alive at Day 100 and eligible to be evaluated for grade 3-4 graft versus host disease

reporting Status

POSTED

time Frame

Day 100

title

Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice